QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)

Medicenna Therapeutics (MDNA) Stock Forecast, Price & News

$0.59
-0.02 (-3.28%)
(As of 05/31/2023 ET)
Compare
Today's Range
$0.58
$0.60
50-Day Range
$0.52
$0.82
52-Week Range
$0.40
$1.88
Volume
7,262 shs
Average Volume
100,681 shs
Market Capitalization
$41.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.50

Medicenna Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
959.1% Upside
$6.25 Price Target
Short Interest
Healthy
0.69% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.20) to ($0.28) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

653rd out of 1,006 stocks

Pharmaceutical Preparations Industry

327th out of 492 stocks


MDNA stock logo

About Medicenna Therapeutics (NASDAQ:MDNA) Stock

Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. It engages in development and commercialization of selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Cytokines for the treatment of cancers. The company was founded by Fahar Merchant and Rosemina Merchant on February 2, 2015 and is headquartered in Toronto, Canada.

Receive MDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MDNA Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
How A.I. Could Make Most 21st Century Diseases EXTINCT
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
MDNA: Update on ABILITY Trial…
Medicenna Extends Period to Exercise Certain Warrants
See More Headlines
Receive MDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MDNA Company Calendar

Last Earnings
11/12/2021
Today
5/31/2023
Next Earnings (Estimated)
6/28/2023
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MDNA
Employees
13
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.25
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$2.50
Forecasted Upside/Downside
+316.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-18,010,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.30 per share

Miscellaneous

Free Float
46,587,000
Market Cap
$41.78 million
Optionable
Not Optionable
Beta
1.23

Key Executives

  • Fahar Merchant
    Chairman, President & Chief Executive Officer
  • Elizabeth Williams
    Chief Financial Officer & Secretary
  • Martin Bexon
    Chief Medical Officer
  • Rosemina Merchant
    Director & Chief Development Officer













MDNA Stock - Frequently Asked Questions

Should I buy or sell Medicenna Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medicenna Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MDNA shares.
View MDNA analyst ratings
or view top-rated stocks.

What is Medicenna Therapeutics' stock price forecast for 2023?

3 Wall Street analysts have issued 1 year target prices for Medicenna Therapeutics' stock. Their MDNA share price forecasts range from $2.50 to $10.00. On average, they anticipate the company's share price to reach $6.25 in the next twelve months. This suggests a possible upside of 941.7% from the stock's current price.
View analysts price targets for MDNA
or view top-rated stocks among Wall Street analysts.

How have MDNA shares performed in 2023?

Medicenna Therapeutics' stock was trading at $0.4580 at the beginning of 2023. Since then, MDNA stock has increased by 31.0% and is now trading at $0.60.
View the best growth stocks for 2023 here
.

When is Medicenna Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 28th 2023.
View our MDNA earnings forecast
.

How were Medicenna Therapeutics' earnings last quarter?

Medicenna Therapeutics Corp. (NASDAQ:MDNA) issued its earnings results on Friday, November, 12th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.03. During the same period in the previous year, the firm earned ($0.06) EPS.

What is Medicenna Therapeutics' stock symbol?

Medicenna Therapeutics trades on the NASDAQ under the ticker symbol "MDNA."

Who are Medicenna Therapeutics' major shareholders?

Medicenna Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Hudson Bay Capital Management LP (1.18%) and Renaissance Technologies LLC (0.22%).

How do I buy shares of Medicenna Therapeutics?

Shares of MDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Medicenna Therapeutics' stock price today?

One share of MDNA stock can currently be purchased for approximately $0.60.

How much money does Medicenna Therapeutics make?

Medicenna Therapeutics (NASDAQ:MDNA) has a market capitalization of $41.78 million. The company earns $-18,010,000.00 in net income (profit) each year or ($0.13) on an earnings per share basis.

How can I contact Medicenna Therapeutics?

Medicenna Therapeutics' mailing address is 200-1920 Yonge Street, Toronto A6, M4S 3E2. The official website for the company is www.medicenna.com. The company can be reached via phone at (416) 648-5555, via email at ir@medicenna.com, or via fax at 416-572-7501.

This page (NASDAQ:MDNA) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -